BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 16210596)

  • 1. Proinflammatory stimulation and pioglitazone treatment regulate peroxisome proliferator-activated receptor gamma levels in peripheral blood mononuclear cells from healthy controls and multiple sclerosis patients.
    Klotz L; Schmidt M; Giese T; Sastre M; Knolle P; Klockgether T; Heneka MT
    J Immunol; 2005 Oct; 175(8):4948-55. PubMed ID: 16210596
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-inflammatory and antiproliferative actions of PPAR-gamma agonists on T lymphocytes derived from MS patients.
    Schmidt S; Moric E; Schmidt M; Sastre M; Feinstein DL; Heneka MT
    J Leukoc Biol; 2004 Mar; 75(3):478-85. PubMed ID: 14657213
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Effects of rosiglitazone on peroxisome proliferator activated receptor-γ pathway in patients with chronic obstructive pulmonary disease].
    Zeng XL; Liu XJ; Bao HR; Zhang Y; Tan EL; Liao JM
    Zhonghua Jie He He Hu Xi Za Zhi; 2011 Oct; 34(10):743-8. PubMed ID: 22321707
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peroxisome proliferator-activated receptor-gamma ligand reduced tumor necrosis factor-alpha-induced interleukin-8 production and growth in endometriotic stromal cells.
    Ohama Y; Harada T; Iwabe T; Taniguchi F; Takenaka Y; Terakawa N
    Fertil Steril; 2008 Feb; 89(2):311-7. PubMed ID: 17555752
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Crosstalk between peroxisome proliferator-activated receptor-γ and mineralcorticoid receptor in TNF-α activated renal tubular cell.
    Xiao J; Chen W; Lu Y; Zhang X; Fu C; Yan Z; Zhang Z; Ye Z
    Inflamm Res; 2015 Aug; 64(8):603-14. PubMed ID: 26072064
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytokines (interferon-γ and tumor necrosis factor-α)-induced nuclear factor-κB activation and chemokine (C-X-C motif) ligand 10 release in Graves disease and ophthalmopathy are modulated by pioglitazone.
    Antonelli A; Ferrari SM; Fallahi P; Piaggi S; Paolicchi A; Franceschini SS; Salvi M; Ferrannini E
    Metabolism; 2011 Feb; 60(2):277-83. PubMed ID: 20206950
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rosiglitazone, a Peroxisome Proliferator-Activated Receptor (PPAR)-γ Agonist, Attenuates Inflammation Via NF-κB Inhibition in Lipopolysaccharide-Induced Peritonitis.
    Zhang YF; Zou XL; Wu J; Yu XQ; Yang X
    Inflammation; 2015 Dec; 38(6):2105-15. PubMed ID: 26047949
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activation of peroxisome proliferator-activated receptor-gamma protects pancreatic beta-cells from cytokine-induced cytotoxicity via NF kappaB pathway.
    Kim EK; Kwon KB; Koo BS; Han MJ; Song MY; Song EK; Han MK; Park JW; Ryu DG; Park BH
    Int J Biochem Cell Biol; 2007; 39(6):1260-75. PubMed ID: 17521952
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The peroxisome proliferator-activated receptor γ agonist pioglitazone prevents NF-κB activation in cisplatin nephrotoxicity through the reduction of p65 acetylation via the AMPK-SIRT1/p300 pathway.
    Zhang J; Zhang Y; Xiao F; Liu Y; Wang J; Gao H; Rong S; Yao Y; Li J; Xu G
    Biochem Pharmacol; 2016 Feb; 101():100-11. PubMed ID: 26673543
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peroxisome proliferator-activated receptor-gamma agonists attenuate angiotensin II-induced collagen type I expression in adventitial fibroblasts.
    Zhang J; Fang NY; Gao PJ; Wu LY; Han WQ; Guo SJ; Shen WL; Zhu DL
    Clin Exp Pharmacol Physiol; 2008 Jan; 35(1):72-7. PubMed ID: 18047631
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The peroxisome proliferator-activated receptor-gamma agonist pioglitazone represses inflammation in a peroxisome proliferator-activated receptor-alpha-dependent manner in vitro and in vivo in mice.
    Orasanu G; Ziouzenkova O; Devchand PR; Nehra V; Hamdy O; Horton ES; Plutzky J
    J Am Coll Cardiol; 2008 Sep; 52(10):869-81. PubMed ID: 18755353
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stimulation of nuclear receptor peroxisome proliferator-activated receptor-γ limits NF-κB-dependent inflammation in mouse cystic fibrosis biliary epithelium.
    Scirpo R; Fiorotto R; Villani A; Amenduni M; Spirli C; Strazzabosco M
    Hepatology; 2015 Nov; 62(5):1551-62. PubMed ID: 26199136
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of peroxisome proliferator-activated receptor activators on tumor necrosis factor-alpha expression in neonatal rat cardiac myocytes.
    Ye P; Fang H; Zhou X; He YL; Liu YX
    Chin Med Sci J; 2004 Dec; 19(4):243-7. PubMed ID: 15669179
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PPAR-γ agonist pioglitazone regulates dendritic cells immunogenicity mediated by DC-SIGN via the MAPK and NF-κB pathways.
    Zhu W; Yan H; Li S; Nie W; Fan F; Zhu J
    Int Immunopharmacol; 2016 Dec; 41():24-34. PubMed ID: 27792919
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Involvement of glucocorticoid receptor and peroxisome proliferator activated receptor-gamma in pioglitazone mediated chronic gastric ulcer healing in rats.
    Lahiri S; Sen T; Palit G
    Eur J Pharmacol; 2009 May; 609(1-3):118-25. PubMed ID: 19281808
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thiazolidinedione ameliorates renal injury in experimental diabetic rats through anti-inflammatory effects mediated by inhibition of NF-kappaB activation.
    Ohga S; Shikata K; Yozai K; Okada S; Ogawa D; Usui H; Wada J; Shikata Y; Makino H
    Am J Physiol Renal Physiol; 2007 Apr; 292(4):F1141-50. PubMed ID: 17190910
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved vascular function upon pioglitazone treatment in type 2 diabetes is not associated with changes in mononuclear NF-kappaB binding activity.
    Rudofsky G; Reismann P; Grafe IA; Konrade I; Djuric Z; Tafel J; Buchbinder S; Zorn M; Humpert PM; Hamann A; Morcos M; Nawroth PP; Bierhaus A
    Horm Metab Res; 2007 Sep; 39(9):665-71. PubMed ID: 17846974
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peroxisome proliferator-activated receptor-γ regulates inflammation and renin-angiotensin system activity in the hypothalamic paraventricular nucleus and ameliorates peripheral manifestations of heart failure.
    Yu Y; Zhang ZH; Wei SG; Weiss RM; Felder RB
    Hypertension; 2012 Feb; 59(2):477-84. PubMed ID: 22083161
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of the PPARgamma activator pioglitazone on p38 MAP kinase and IkappaBalpha in the spinal cord of a transgenic mouse model of amyotrophic lateral sclerosis.
    Shibata N; Kawaguchi-Niida M; Yamamoto T; Toi S; Hirano A; Kobayashi M
    Neuropathology; 2008 Aug; 28(4):387-98. PubMed ID: 18312546
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PPAR-γ agonist pioglitazone protects against IL-17 induced intervertebral disc inflammation and degeneration via suppression of NF-κB signaling pathway.
    Liu Y; Qu Y; Liu L; Zhao H; Ma H; Si M; Cheng L; Nie L
    Int Immunopharmacol; 2019 Jul; 72():138-147. PubMed ID: 30981079
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.